Table 1: Dual CGRP Sequence										
Secondary CGRP										
		Fremanezumab (N=10)	Galcanezuma b (N=3)	Eptinezuma b (N=0)	Ubrogepant (N=6)	Rimegepant (N=8)	Atogepant (N=0)			
Initial CGRP	Fremanezuma b (N=11)	0	0	0	5	6	0			
	Galcanezuma b (N=3)	0	0	0	1	2	0			
	Epitenezumab (N=0)	0	0	0	0	0	0			
	Ubrogepant (N=11)	9	2	0	0	0	0			
	Rimegepant (N=2)	1	1	0	0	0	0			
	Atogepant (N=0)	0	0	0	0	0	0			

Table 2: Change in Headache Frequency, Severity, and Duration									
		P	Patient Group						
Characteristic	Overall N=90	Dual-CGRP N=27	Mono-CGRP N=63	P value ²					
Change in Migraine Frequency (days)	0.0 (-5.8, 0.0) ¹	-4.0 (-14.0-0.0) ¹	0.0 (-5.0, 0.0) 1	0.112					
Change in Headache Severity (0-10 scale)	-1.0 (-2.0, 0.0) ¹	-2.0 (-2.5, 0.0) ¹	-1.0 (-2.0, 0.0) ¹	0.039					
Change in Max Severity (0-10 scale)	-2.0 (-2.0, 0.0) ¹	-2.0 (-2.0, 0.0) ¹	-2.0 (-2.0, 0.0) ¹	0.305					
Change in Headache Duration (hours)	0.0 (0.0, 0.0) ¹	0.0 (0.0, 0.0) ¹	0.0 (0.0,0.0) ¹	0.423					
¹ mean (range) ² Wilcoxon rank sum tes	t								